The novel P2Y12 antagonist AZD6140 rapidly and reversibly reduces platelet activation in diabetic rats

Thrombosis Research

Volumn 125, Issue 3, 2010, Pages

  Flierl, Ulrike ^a   Schöpp, Corinna ^a   Jaitner, Juliane ^a   Bauersachs, Johann ^a   Schäfer, Andreas ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

ADP receptors; diabetes; P2Y12; Platelet activation

Indexed keywords

ADENOSINE DIPHOSPHATE; FIBRINOGEN; PADGEM PROTEIN; TICAGRELOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY BLOOD FLOW; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; LAMINAR FLOW; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

EID: 76949091471     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.09.025     Document Type: Article

References (42)

1. Resnick H.E., Harris M.I., Brock D.B., and Harris T.B. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 23 (2000) 176-180
2. Tschoepe D., and Menart-Houtermans B. Diabetes mellitus. In: Michelson A.D. (Ed). Platelets vol. 29 (2002), Academic Press, San Diego 435-445
3. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
4. Ryden L., Standl E., Bartnik M., Van den B.G., Betteridge J., de Boer M.J., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28 (2007) 88-136
5. Huo Y., Schober A., Forlow S.B., Smith D.F., Hyman M.C., Jung S., et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 9 (2003) 61-67
6. Massberg S., Brand K., Gruner S., Page S., Muller E., Muller I., et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 196 (2002) 887-896
7. The CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
8. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., Jacobs A.K., Kern M.J., King III S.B., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) 156-175
9. Bliden K.P., DiChiara J., Tantry U.S., Bassi A.K., Chaganti S.K., and Gurbel P.A. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. J Am Coll Cardiol 49 (2007) 657-666
10. O'Donoghue M., and Wiviott S.D. Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?. Circulation 114 (2006) e600-e606
11. Grossmann R., Sokolova O., Schnurr A., Bonz A., Porsche C., Obergfell A., et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 92 (2004) 1201-1206
12. Gurbel P.A., and Tantry U.S. Aspirin and clopidogrel resistance: consideration and management. J Interv Cardiol 19 (2006) 439-448
13. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
14. Wiviott S.D., and Antman E.M. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 109 (2004) 3064-3067
15. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24 (2004) 1980-1987
16. Schäfer A., Weinberger S., Flierl U., Eigenthaler M., Störk S., Walter U., et al. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. Thromb Haemost 100 (2008) 618-625
17. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., et al. Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease. Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study. Circulation 115 (2007) 708-716
18. Springthorpe B., Bailey A., Barton P., Birkinshaw T.N., Bonnert R.V., Brown R.C., et al. From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett 17 (2007) 6013-6018
19. Husted S., Emanuelsson H., Heptinstall S., Sandset P.M., Wickens M., and Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y(12) antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27 (2006) 1038-1047
20. Van Giezen J.J., Nilsson L., Berntsson P., Wissing B.M., Giordanetto F., Tomlinson W., et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 7 (2009) 1556-1565
21. Storey R.F., Husted S., Harrington R.A., Heptinstall S., Wilcox R.G., Peters G., et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 50 (2007) 1852-1856
22. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 361 (2009) 1045-1057
23. Kroll M.H., Hellums J.D., McIntire L.V., Schafer A.I., and Moake J.L. Platelets and shear stress. Blood 88 (1996) 1525-1541
24. Savage B., Saldivar E., and Ruggeri Z.M. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 84 (1996) 289-297
25. Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 46 (2006) 277-300
26. Montalescot G., Sideris G., Meuleman C., Bal-dit-Sollier C., Lellouche N., Steg P.G., et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 48 (2006) 931-938
27. Cuisset T., Frere C., Quilici J., Morange P.E., Nait-Saidi L., Carvajal J., et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 48 (2006) 1339-1345
28. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
29. The BARI investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol 49 (2007) 1600-1606
30. Berry C., Tardif J.C., and Bourassa M.G. Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization. J Am Coll Cardiol 49 (2007) 643-656
31. Husted S., Harrington R.A., Cannon C.P., Storey R.F., Mitchell P., and Emanuelsson H. Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial. Int J Clin Pract 63 (2009) 667-670
32. Fateh-Moghadam S., Li Z., Ersel S., Reuter T., Htun P., Plöckinger U., et al. Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type II. Arterioscler Thromb Vasc Biol 25 (2005) 1299-1303
33. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., et al. Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease. Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study. Circulation 115 (2007) 708-716
34. Hodgson J., Stone G.W., Lincoff A.M., Klein L., Walpole H., Bottner R., et al. Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions drug-eluting stent task force. Cath Cardiovasc Interv 69 (2007) 327-333
35. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
36. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
37. Muller I., Besta F., Schulz C., Massberg S., Schonig A., and Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89 (2003) 783-787
38. Gurbel P.A., Bliden K.P., Guyer K., Cho P.W., Zaman K.A., Kreutz R.P., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol 46 (2005) 1820-1826
39. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., et al. Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease. Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study. Circulation 115 (2007) 708-716
40. Gurbel P.A., Bliden K.P., Samara W., Yoho J.A., Hayes K., Fissha M.Z., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 46 (2005) 1827-1832
41. Wenaweser P., Dorffler-Melly J., Imboden K., Windecker S., Togni M., Meier B., et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 45 (2005) 1748-1752
42. Glowczynska R., Malek L.A., Spiewak M., Filipiak K.J., Grabowski M., Kisiel B., et al. Clinical, biochemical and genetical resistance to clopidogrel in a patient with the recurrent coronary stent thrombosis-a case report and review of the literature. Int J Cardiol 111 (2006) 326-328